Biomarin Pharmaceutical | 8-K: Current report
51minutes ago
Biomarin Pharmaceutical | DEF 14A: Definitive information statements
Apr 9 22:19 ET
Biomarin Pharmaceutical | DEFA14A: Others
Apr 9 16:13 ET
Biomarin Pharmaceutical | 8-K: BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
Feb 22 16:10 ET
Biomarin Pharmaceutical | 8-K: Current report
Jan 11 00:00 ET
Biomarin Pharmaceutical | 8-K: Current report
Dec 20, 2023 17:22 ET
Biomarin Pharmaceutical | 8-K: Current report
Nov 3, 2023 16:07 ET
Biomarin Pharmaceutical | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Nov 2, 2023 16:09 ET
Biomarin Pharmaceutical | 8-K: BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
Nov 1, 2023 16:09 ET
Biomarin Pharmaceutical | 8-K: BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date
Jul 31, 2023 16:05 ET
Biomarin Pharmaceutical | 8-K: Current report
May 30, 2023 16:11 ET
Biomarin Pharmaceutical | 8-K: BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues • Growth of VOXZOGO ® Accelerated with Rapid Uptake in Japan and Brazil Resulting in Increased Full-year 202
Apr 26, 2023 16:07 ET
Biomarin Pharmaceutical | DEFA14A: Others
Apr 11, 2023 16:31 ET
Biomarin Pharmaceutical | DEF 14A: Definitive proxy statements
Apr 11, 2023 16:30 ET
Biomarin Pharmaceutical | 8-K: Current report
Feb 27, 2023 16:10 ET
Biomarin Pharmaceutical | 8-K: Current report
Jan 11, 2023 16:18 ET
Biomarin Pharmaceutical | 8-K: Current report
Dec 21, 2022 16:06 ET
Biomarin Pharmaceutical | 8-K: Current report
Oct 26, 2022 16:14 ET
Biomarin Pharmaceutical | 8-K: Current report
Oct 6, 2022 19:01 ET
Biomarin Pharmaceutical | 8-K: Current report
Sep 12, 2022 08:30 ET
No Data
No Data